Centrus Energy Corp. reports first-quarter results today against a backdrop that is one of the most charged in the uranium enrichment space: short sellers hold nearly a quarter of the free float, the lending pool is close to exhausted, and a violent post-earnings sell-off from February still sits fresh in the data.
The short positioning here is genuinely extreme. Short interest runs at 24.1% of the free float — ranking in the 2nd percentile of the entire universe on ORTEX's short-score rank, with the short score itself at 73.1 and climbing steadily through the past two weeks. The lending market reinforces the picture: availability has tightened to near-zero, with the borrow pool hitting 100% fully deployed on multiple sessions across April, and currently running at 95.75% — meaning fewer than one share remains available for every twenty already borrowed. Cost to borrow, at 0.87%, remains low in absolute terms, which tells you the constraint here is quantity, not price: there simply is not much left to lend. Short interest has eased roughly 8% over the past month, but the week-on-week reading edged back up 0.6%, suggesting covering has stalled.
Options positioning is modestly more cautious than recent norms, though not dramatically so. The put/call ratio has drifted to 0.73, about 1.2 standard deviations above its 20-day average of 0.70 — a mild tilt toward protection, but nowhere near the defensive extremes the stock has seen over the past year (the 52-week PCR high is 1.27). That gap matters: options traders are hedging, but not in a way that signals deep fear. The stock itself is up 12.5% over the past month to $206.04, clawing back ground after a brutal February, when the last confirmed earnings event triggered a one-day drop of roughly 30% and a five-day loss approaching 22%.
The fundamental debate splits cleanly. Bulls point to the $900 million DOE award, structural demand for domestic uranium enrichment, and Centrus's monopoly position on certain defence-critical capabilities — with Needham holding a $357 target and B. Riley maintaining Buy despite trimming its target to $295 from $315 earlier in April. Bears anchor on execution risk: the TENEX relationship, dependence on federal funding, and the potential for dilutive equity issuance to finance growth. JP Morgan and Citi both hold Neutral ratings, and the Street's mean target of $269 implies meaningful upside from current levels — but the direction of travel has been downward across most recent revisions. Institutionally, State Street added 410,000 shares and Van Eck added 306,000 in the most recent quarter, while the P/E has re-rated up roughly 4 turns over the past 30 days to 52x, reflecting the recent price recovery.
The print will test whether Centrus's enrichment revenue trajectory and DOE contract progress can justify a multiple that has expanded sharply even as analysts have trimmed their targets — and whether a short base that has barely moved in two weeks is positioned to cover or dig in further.
See the live data behind this article on ORTEX.
Open LEU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
